MCCB

Global Low Voltage Switchgear (LVSG) Industry Report 2023-2028: Advancements of Electricity Infrastructure, Installation of Heat Pumps and Retrofit of Energy-efficient Equipment Bolsters Growth

Retrieved on: 
Thursday, March 14, 2024
Internet of things, Electricity, Lighting, HVAC, RCCB, ACB, MCCB, MCB

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Global Low Voltage Switchgear (LVSG) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 14, 2024 /PRNewswire/ -- The "Global Low Voltage Switchgear (LVSG) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • In 2022, the global LVSG market registered a slim growth rate of 0.8% due to post-pandemic effects on the economy, such as material shortages, cost inflation, and logistics issues.
  • In 2022, the Asia-Pacific (APAC) LVSG market accounted for 36.7% of the global market revenue.
  • The report has also identified four major growth opportunity areas, which are data centers, electrification, residential heat pumps, and building construction.

Global Low Voltage Switchgear Market Report 2023: Data Centers, Charging Infrastructure and Residential Projects as Key Prospects for Vertical Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, December 1, 2023
Other Energy, Energy, MCB, Electricity, HVAC, Lighting, RCCB, Bel Air Circuit, Internet of things, MCCB, ACB

The "Global Low Voltage Switchgear (LVSG) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Low Voltage Switchgear (LVSG) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • In 2022, the global LVSG market registered a slim growth rate of 0.8% due to post-pandemic effects on the economy, such as material shortages, cost inflation, and logistics issues.
  • In 2022, the Asia-Pacific (APAC) LVSG market accounted for 36.7% of the global market revenue.
  • The report has also identified four major growth opportunity areas, which are data centers, electrification, residential heat pumps, and building construction.

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Retrieved on: 
Thursday, August 10, 2023
Consensus, Psilocybin, Sequela, PK, Partnership, MCCB, PD, CPT, CSO, OTF, Perception, Continuity, Anorexia nervosa, QT interval, Aes, Pharmacokinetics, Neuroscience, OUD, Cmax, MOAA, Language, QT, American Medical Association, Plasma, Cardiac electrophysiology, Patient, Investment, Current Procedural Terminology, Risk, Administration, AUC, Pivotal, Imperial College London, Entrepreneurship, Research and development, Cardiology, Research, SQ, R, TRD, Arrhythmia, III, Schizophrenia, Cognitive deficit, PTSD, Safety, Disease, Nursing, Pharmaceutical industry, Vaccine, Palladium, Medical device, Surveying, Cryptocurrency, Ibogaine

“Looking ahead to the second half of 2023 and beyond, we believe we are well positioned to continue advancing our key clinical programs.

Key Points: 
  • “Looking ahead to the second half of 2023 and beyond, we believe we are well positioned to continue advancing our key clinical programs.
  • Drug-induced prolongation of the QT interval is a phenomenon that has been, with many but not all drugs, associated with cardiac arrhythmias.
  • The single-blinded Phase 1 study assessed the safety, tolerability and pharmacokinetics of single-ascending doses of DMX-1002 in healthy volunteers.
  • Enrollment has been recently completed and the company expects to report initial clinical data in Q4 2023.

Electric Fuse Market Predicted to Make a Robust Comeback After the Pandemic Debacle with a Striking CAGR of 7.7% in the 2022-2031 Timeframe [280-Pages] | Disclosed by Research Dive

Retrieved on: 
Monday, May 29, 2023
MCCB, Urbanization, Electricity, Growth, MCB Bank, Completeness, COVID-19, Investment, Coal, Renewable energy

NEW YORK, May 29, 2023 /PRNewswire/ -- Global Electric Fuse Market Forecast Analysis:

Key Points: 
  • The global electric fuse market is expected to witness prominent growth by 2031, due to the increasing applications of electric fuses in the industrial sector.
  • NEW YORK, May 29, 2023 /PRNewswire/ -- Global Electric Fuse Market Forecast Analysis:
    As per the report published by Research Dive, the global electric fuse market is anticipated to generate a revenue of $9,246.3 million and rise at a healthy CAGR of 7.7% over the analysis timeframe from 2022 to 2031.
  • To get access to the Complete PDF Sample of Electric Fuse Market Click Here!
  • The outbreak of the Covid-19 pandemic has had a negative impact on the electric fuse market, likewise, various other industries.

Electric Fuse Market Predicted to Make a Robust Comeback After the Pandemic Debacle with a Striking CAGR of 7.7% in the 2022-2031 Timeframe [280-Pages] | Disclosed by Research Dive

Retrieved on: 
Monday, May 29, 2023
MCCB, Urbanization, Electricity, Growth, MCB Bank, Completeness, COVID-19, Investment, Coal, Renewable energy

NEW YORK, May 29, 2023 /PRNewswire/ -- Global Electric Fuse Market Forecast Analysis:

Key Points: 
  • The global electric fuse market is expected to witness prominent growth by 2031, due to the increasing applications of electric fuses in the industrial sector.
  • NEW YORK, May 29, 2023 /PRNewswire/ -- Global Electric Fuse Market Forecast Analysis:
    As per the report published by Research Dive, the global electric fuse market is anticipated to generate a revenue of $9,246.3 million and rise at a healthy CAGR of 7.7% over the analysis timeframe from 2022 to 2031.
  • To get access to the Complete PDF Sample of Electric Fuse Market Click Here!
  • The outbreak of the Covid-19 pandemic has had a negative impact on the electric fuse market, likewise, various other industries.

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

Retrieved on: 
Thursday, May 11, 2023
Well, Consensus, Psilocybin, Acceleration, PK, Insurance, GABA, DMT, Society, MCCB, PD, IV, D&O, Benzodiazepine, OTF, VAT, Anorexia nervosa, COMP, PTSD, G&A, Part, Accounting, Anxiety disorder, Patient, Investment, Administration, EEG, Biological Psychiatry (journal), Annual general meeting, Pivotal, CIAS, Entrepreneurship, Oxygen toxicity, Research and development, Research, R, TRD, Safety, Cognitive deficit, Pharmaceutical industry, Palladium, Bank, Surveying, Schizophrenia

The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.

Key Points: 
  • The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.
  • NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates.
  • “This past quarter we made significant progress, including the dosing of the first patient with RL-007 in a randomized, placebo-controlled Phase 2 study.
  • In January 2023, Phase 1 results were announced from the study of GRX-917 in healthy volunteers.

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Retrieved on: 
Friday, March 24, 2023
Consensus, Cognition, Acceleration, GABA, Etifoxine, MCCB, Quantitative electroencephalography, Benzodiazepine, Anxiety, COMP, Brain, COMPASS, Patient, Standard of care, CIAS, Pivotal, Entrepreneurship, TRD, Mental health, Nursing, Vaccine, Pharmaceutical industry, Medical imaging

Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.

Key Points: 
  • Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.
  • More details of the phase 2 clinical development plan will be provided upon initiation of the study.
  • In January 2022, positive results were announced from the phase 1 single and multiple ascending dose study of GRX-917.
  • In the fourth quarter of 2022, the first subject was dosed in a Phase 1 study of VLS-01.

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

Retrieved on: 
Monday, December 19, 2022
Consensus, Clinical trial, Psychosis, MCCB, Disability, Brain, Biomarker, Cognitive deficit, Disease, Government budget balance, Patient, Family, Pharmacology, Atai, Life expectancy, Safety, FDA, Cognition, Pharmaceutical industry, Medical imaging, CIAS, Schizophrenia

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS).

Key Points: 
  • The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS).
  • NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its Phase 2b proof-of-concept clinical trial for RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS), a condition for which there are currently no FDA-approved treatments.
  • The Phase 2b trial is a randomized, placebo-controlled, double-blind, 3-arm study evaluating 2 doses of RL-007 and a placebo among 234 patients.
  • The disease is frequently associated with significant distress and impairment in personal, family, social, educational, occupational, and other important areas of life.

Henry Schein Completes Acquisition of Condor Dental

Retrieved on: 
Thursday, July 7, 2022
Surgery, Medical Devices, Health, Dental, Medical Supplies, FDA, Health, Annual report, Acquisition, Patient, Care Act 2014, Epidemic, Supply chain, S&P, Disease, COVID-19, Condor, Workforce, MCCB, Laboratory, Pandemic, Failure, Company, Industry, Intellectual property, PPE, Public health, Breast implant, Health information management, Affordable Care Act, U.S. Securities and Exchange Commission, Henry Schein, Terrorism, Partnership, Privacy, Private Securities Litigation Reform Act, Lists of disasters, Nasdaq, Henry Schein, Inc. v. Archer & White Sales, Inc., EPS, SEC, Risk, Solution, Risk factor, Vaccine, Board, Government, Novel coronavirus, Collection, Dentistry, Pharmaceutical industry, Technology

Henry Schein, Inc. (Nasdaq: HSIC), the worlds largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of Condor Dental Research Company SA (Condor Dental), a dental distribution company that serves dental general practitioners, specialists, and laboratories in Switzerland.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC), the worlds largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of Condor Dental Research Company SA (Condor Dental), a dental distribution company that serves dental general practitioners, specialists, and laboratories in Switzerland.
  • The addition of Condor Dental will expand Henry Scheins entry into the Swiss market for its dental distribution business.
  • We at Henry Schein welcome our new Condor Dental colleagues and we look forward to bringing new products, services, and solutions to the Swiss dental community."
  • As part of the Henry Schein family, Condor Dental has several exciting opportunities to accelerate organic growth including geographic expansion, leveraging Henry Scheins private-label products, and accelerating participation in the digitalization of dental practices.

Schneider Electric’s Next Generation PowerPacT Circuit Breaker Wins Showstopper Award at NECA Nashville 2021 

Retrieved on: 
Tuesday, October 12, 2021
Technology, Other Construction & Property, Residential Building & Real Estate, Other Energy, Commercial Building & Real Estate, Utilities, Construction & Property, Alternative Energy, Engineering, Energy, Other Technology, Manufacturing, Software, Building Systems, Environment, Hardware, Data Management, Life, Schneider Electric, Efficiency, Automation, Technology, Locator, Schneider, Showcase, Software, Electricity, LED, MCCB, Solution, Partnership, Sustainability, Zigbee, Electronic component, Instrumentation, Video game console, Risk management

Schneider Electric , the global leader in the digital transformation of energy management and automation and the industrys leader in circuit breakers, has won the NECA Showstopper Award following the unveiling of its new and improved PowerPacTTM Molded Case Circuit Breaker (MCCB) series at the 2021 NECA Convention Nashville .

Key Points: 
  • Schneider Electric , the global leader in the digital transformation of energy management and automation and the industrys leader in circuit breakers, has won the NECA Showstopper Award following the unveiling of its new and improved PowerPacTTM Molded Case Circuit Breaker (MCCB) series at the 2021 NECA Convention Nashville .
  • The annual Showstopper Showcase at the NECA Convention and Trade Show highlights products and services recently introduced to the market.
  • Selected from a diverse range of innovative new products, Schneider Electrics PowerPacT circuit breaker offers an improved circuit breaker solution for the future.
  • The new generation of PowerPacT circuit breakers brings innovative technology designed to meet the needs of Schneider Electrics customers, offering an improved solution for today and the future.